Charles River Laboratories | CRL - Debt



Charles River Laboratories reported $2.79B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Agilent USD 3.41B 86M Jul/2025
Align Technology USD 118.54M 118.54M Mar/2025
Bio-Rad Laboratories USD 1.41B 204.6M Jun/2025
Bruker USD 2.44B 321.5M Jun/2025
Cardinal Health USD 8.53B 848M Jun/2025
Charles River Laboratories USD 2.79B 275.28M Jun/2025
Cigna USD 30.77B 320M Jun/2025
CVS Health USD 82.72B 18.01B Jun/2025
Danaher USD 17.36B 878M Jun/2025
Dentsply International USD 2.49B 159M Jun/2025
Elevance Health USD 30.19B 183M Jun/2025
Galapagos EUR 10.86M 864K Mar/2025
Hologic USD 2.52B 8.5M Jun/2025
Humana USD 12.59B 1.3B Jun/2025
Illumina USD 2.6B 608M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
IQVIA Holdings USD 15.49B 1.16B Jun/2025
Laboratory Of America USD 6.52B 107.7M Mar/2025
Lonza CHF 4.71B 915M Dec/2024
McKesson USD 9.93B 4.28B Jun/2025
Merck EUR 9.4B 704M Jun/2025
Mettler Toledo International USD 2.18B 109.83M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Quest Diagnostics USD 6.38B 525M Jun/2025
Revvity USD 3.17B 17.91M Mar/2025
Thermo Fisher Scientific USD 34.19B 2.91B Mar/2025
United Therapeutics USD 200M 100M Mar/2025
UnitedHealth USD 79.19B 2.08B Jun/2025
Waters USD 1.54B 81.64M Jun/2025
West Pharmaceutical Services USD 202.6M 0 Jun/2025